Crisis Management for Unprotected Exposure

Postinor is relevant for easing symptoms that interfere with daily functioning, such as the acute risk status following unprotected sexual intercourse. Its primary therapeutic use may be part of symptomatic management to help reduce the likelihood of pregnancy following unprotected or under-protected sex. It is applied in clinical settings that involve acute or unstable symptom patterns related to unprotected exposure, providing supportive relief in situations requiring short-term symptomatic support.

---

Intervention and Provision of Acute Reproductive Safety

Postinor is commonly used across conditions involving episodic or fluctuating manifestations, such as an unexpected failure of a primary contraceptive method, and in scenarios requiring short-term symptomatic assistance. The medication is relevant for easing symptoms that interfere with daily comfort, such as the distress associated with sudden contraceptive failure. The therapeutic focus encompasses situations of unprotected exposure and contraceptive failure, and is relevant in contexts marked by increased discomfort or tension for women of childbearing age.

“This intervention contributes to maintaining functional stability during phases of increased distress or discomfort.”

Quick Fact: Relief for Acute Contraceptive Risk
This medication is relevant for easing the stress associated with uncertainty following a high-risk event, supporting general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus guidance

Postinor (levonorgestrel) is officially indicated for emergency contraception in females of reproductive age who are not currently pregnant following unprotected intercourse or contraceptive failure. The product is strictly not intended for use as a form of routine contraception.

Contraindications and Restrictions

The medicine is contraindicated if pregnancy is known or suspected, as it is ineffective once implantation has occurred. Individuals with a known hypersensitivity to levonorgestrel or any tablet excipients must also not use this product.

Category	Eligibility Rule
Age Restriction	The product is not indicated for females before menarche or postmenopausal women.
Hepatic Function	Use is not recommended in patients with severe hepatic dysfunction (severe liver disease) due to the drug's metabolism.
Comorbidities	Caution is advised for those with malabsorption syndromes (e.g., Crohn's disease) or a history of ectopic pregnancy, as these conditions may either reduce efficacy or increase risk.

Pregnancy and Lactation

Use during pregnancy is contraindicated. However, levonorgestrel is generally considered the hormonal contraceptive of choice during lactation and is permitted while breastfeeding.

Official Interaction Profile for Postinor

The interaction profile of Postinor (Levonorgestrel) is defined primarily by its metabolism in the liver. Concomitant use with certain medicinal or herbal products may significantly alter the concentration of the active ingredient, which is noted in regulatory documents as potentially reducing the product's effectiveness.

Interaction Type	Examples of Interacting Substances (Per Label)
Exposure-Decreasing Interactions	Anti-epilepsy medicines (e.g., Phenytoin, Carbamazepine, Barbiturates); Anti-tuberculosis medicines (e.g., Rifampicin); HIV treatments (e.g., Efavirenz, Ritonavir); other agents (Griseofulvin, Bosentan).
Herbal Product Interactions	St. John's wort (Hypericum perforatum).
Other Pharmacodynamic Effects	Cyclosporin (Levonorgestrel may inhibit its metabolism, potentially increasing the risk of toxicity).

The official regulatory documents state that the primary mechanism for these Exposure-Decreasing Interactions is Hepatic Enzyme Induction, mainly involving the CYP3A4 enzyme system. The co-administration of such inducers leads to the enhanced metabolism and subsequent decrease in the plasma levels of levonorgestrel.

Interaction-Related Constraints

No combination is formally classified as a drug-drug contraindication. However, due to the metabolic role of the liver, the product is not recommended for use in patients with severe hepatic dysfunction. No official regulatory information dictates mandatory timing separation rules for the administration of Postinor with other medicines or food.

Central Modulation of the HPO Axis

Postinor, containing the synthetic progestogen levonorgestrel, acts primarily on the hypothalamic-pituitary-ovarian (HPO) axis, the body's central hormonal regulatory system. Its key mechanism involves suppressing the surge of Luteinizing Hormone (LH) from the pituitary gland. This targeted interference with the hormonal feedback loop suppresses the ovulatory process, as the LH surge is the necessary signal to trigger the release of an egg.

---

Progesterone Receptor Agonism and Downstream Cascades

Levonorgestrel exerts its biological effect by acting as an agonist (activator) on progesterone receptors located across reproductive tissues. This receptor binding initiates signal transduction, mimicking the activity of natural progesterone, which subsequently modulates the activity of the HPO axis and induces secondary alterations in the reproductive tract.

---

Peripheral Changes in Reproductive Tract Fluids

As a secondary effect, the drug modulates the physiological processes of the cervix. It causes a rapid alteration in the consistency of cervical mucus, leading to it becoming thicker and less permeable. This mechanism limits the passage of sperm, and these peripheral changes shape the drug's total mechanistic profile.

How to Use Postinor (Levonorgestrel) — Official Administration Guidelines

Postinor, which contains levonorgestrel, is an emergency contraceptive pill with usage instructions. Correct administration is time-critical and follows a standardized protocol.

---

Administration Scope and Dosing

Category	Official Instruction
Route of Administration	Oral (swallowing the tablet whole with water)
Standard Dosing Regimen	One single tablet containing 1.5 mg of levonorgestrel.
Timing Constraint	Must be taken as soon as possible, preferably within 12 hours, but no later than 72 hours (3 days) following unprotected intercourse.
Relation to Meals	Can be taken with or without food.

---

Procedural and Conditional Rules

1. Time is Critical: The treatment must be initiated promptly; efficacy decreases significantly with delay. The 72-hour limit is the established maximum for initiation.
2. Vomiting Protocol: If vomiting occurs within 3 hours of taking the tablet, an immediate replacement tablet must be taken to ensure the full dose is absorbed.
3. Course Restriction: This medication is approved for a single course of treatment (emergency measure only). Repeated administration within the same menstrual cycle is generally not advisable and is not part of the standard usage protocol.
4. Age-Group Use: The medication is indicated for use in adults and adolescents of childbearing potential, following the standard 1.5 mg dose. Dose adjustments based on age are not part of the official label.

Recent Clinical Evidence Overview

Postinor, containing the progestin levonorgestrel (LNG), is an established method of emergency contraception. Recent clinical studies have focused on refining its mechanism of action, confirming efficacy rates, and evaluating optimal timing.

---

Mechanism of Action Findings

Studies suggest that the primary way levonorgestrel works is by interfering with ovulation. If taken before the surge of Luteinizing Hormone (LH) begins—the hormonal signal that precedes the release of an egg—LNG can inhibit or delay ovulation. If no egg is released, fertilization cannot occur.

• Key Distinction: A large body of evidence indicates that LNG does not prevent the implantation of a fertilized egg and does not terminate an existing pregnancy.

---

Efficacy and Timing

Efficacy for levonorgestrel-only emergency contraception is highly dependent on how soon the dose is taken following unprotected intercourse. Clinical trials show that taking the dose closer to the event is associated with a greater likelihood of preventing pregnancy.

Timing after Unprotected Intercourse	Estimated Efficacy in Preventing Expected Pregnancies
Within 24 hours	Up to 95%
Within 72 hours (3 days)	Up to 85%
After 72 hours	Efficacy is significantly reduced

It is important to note that the effectiveness of the drug may also be reduced in individuals with higher body mass indices (BMI geq 30 kg/m^2), although this factor is not considered significant enough to restrict its use.

---

Safety and Side Effects Research

Levonorgestrel has been widely studied and is generally considered safe and well-tolerated. Common side effects reported in clinical trials are mild and temporary, primarily including nausea, headache, dizziness, and changes in the menstrual bleeding pattern, such as spotting or a temporary delay in the next menstrual period.

Common questions about Postinor (FAQ)

Q: How quickly does Postinor need to be taken to be effective?

Postinor should be taken as soon as possible after unprotected sexual intercourse. According to prescribing information, the medication is most effective when taken within the first 72 hours (3 days). Efficacy may decrease the longer the time between intercourse and administration.

Q: Can Postinor be used as a regular method of contraception?

Postinor is intended for use only as an emergency contraceptive method. It is not recommended for routine use. It is less effective than regular, barrier, or long-term contraceptive methods and does not offer protection against sexually transmitted infections (STIs).

Q: What are the most common side effects of Postinor?

Common side effects observed in clinical data may include nausea, fatigue, headache, and abdominal pain. Changes to the next menstrual cycle, such as timing or flow, may also occur. These effects are generally temporary.

How to Store and Dispose of Postinor (Levonorgestrel)

The official labeling for Postinor mandates specific storage and disposal requirements to maintain product stability and ensure household safety.

---

Storage Requirements

Postinor must be kept out of the sight and reach of children.

Storage Constraint	Required Condition
Temperature	Store below 25 C in a cool, dry place.
Protection	Keep in the original package to protect from light.
Container	Keep in the original container, tightly closed, away from excess heat and moisture (not in the bathroom).
Stability	Do not use the medicine after the expiry date printed on the package.

---

Disposal Instructions

Expired or unused Postinor must be discarded according to established pharmaceutical waste protocols.

• Do not throw away medicines via wastewater or household waste.
• Consult a pharmacist for guidance on proper disposal to help protect the environment.